Press Release · Press Releases
Quantinuum veröffentlicht Ergebnisse für das dritte Quartal 2026 und hebt Umsatzprognose für das Gesamtjahr an
Der Umsatz im dritten Quartal stieg im Vergleich zum Vorjahreszeitraum um 233 %; die Umsatzprognose für das Geschäftsjahr 2026 wurde angehoben Ausbau der Branchenführerschaft im Bereich der Fehlertoleranz durch zwei aufeinanderfolgende Weltrekorde, die den glaubwürdigsten Weg zu...
This press release summary is reproduced from the issuer's public feed.
Read the full release at PR NewswireOriginal publisher: PR Newswire
Spotted an error? Request a correction · Corrections Policy
Related stories
Routine Invasive Procedures for Stable Heart Disease Offer No Long-Term Survival Advantage Over Drug Therapy
Findings Add to Past Evidence That Early Invasive Procedures Ease Symptoms but Do Not Improve Long-Term Survival NEW YORK, Nov. 7, 2026 /PRNewswire/ -- Patients with stable heart disease and abnormal stress tests who have invasive procedures early in their care do not live longer than...
PR Newswire ·
What to Look for in an Online GLP-1 Provider: Meant Outlines Five Questions Worth Asking Before Signing Up
MANASSAS, Va., Nov. 7, 2026 /PRNewswire/ -- As more telehealth companies offer GLP-1 care, the options can look alike from the outside, and telling them apart takes more than a glance at a landing page. Meant is sharing five questions consumers can ask when choosing an online GLP-1...
PR Newswire ·
Notice of AUR Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Aurora Innovation, Inc. (AUR) Investors to Contact the Firm
RADNOR, Pa., Nov. 7, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Aurora Innovation, Inc. ("Aurora Innovation") (NASDAQ: AUR) on...
PR Newswire ·
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more...
PR Newswire ·
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16 ICOTYDE is a first-in-class IL-23R targeted oral peptide,...
PR Newswire ·
FCEL 4-DAY DEADLINE ALERT: Hagens Berman Encourages FuelCell Energy Investors with Losses to Contact Firm Before Nov. 10th Deadline in Securities Class Action
SAN FRANCISCO, Nov. 7, 2026 /PRNewswire/ -- National trial law firm Hagens Berman alerts investors in FuelCell Energy, Inc. (NASDAQ: FCEL) that a securities class action has been filed, and reminds investors that they have until November 10, 2026, to seek appointment as lead plaintiff. If...
PR Newswire ·